Triallo Logo
  • Home
  • Search
  • Contact

Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty

Triallo

Triallo is a platform that connects patients with life-changing clinical trials. Find hope, access innovative treatments, and contribute to medical breakthroughs.


© 2026 Triallo. All rights reserved.

Privacy PolicyTerms of Service
1021-1040 of 1,782 trials

Diffuse Large B-Cell Lymphoma: Axicabtagene Ciloleucel Study

We are studying a new treatment for patients with late relapse of diffuse large B-cell lymphoma to see if it improves their condition and quality of life. The trial also looks at the safety of this treatment.

Recurrent B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Vaginal Progesterone for IVF: Improving Live Birth Rates

We are studying whether vaginal progesterone helps women achieve live births after frozen embryo transfer. The trial compares outcomes between those receiving progesterone and those who do not.

Infertility≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Prostate Cancer Diagnosis: 18F-PSMA PET/MRI Study

We are testing a new imaging method to see how well it identifies clinically significant prostate cancer. This may help improve diagnosis accuracy for patients.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyUrology

Vulvar Squamous Cell Carcinoma: Pembrolizumab Study

We are studying whether Pembrolizumab can help shrink tumors in patients with vulvar squamous cell carcinoma before surgery. This trial also looks at how the treatment affects the immune system.

Vulvar Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

IgG4-Related Disease: Abatacept Treatment Study

We are investigating whether abatacept can help reduce the risk of disease recurrence in people with IgG4-related disease. This study aims to provide insights into a new treatment option for managing this condition.

IgG4-Related Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Tocolysis for Preterm Premature Rupture of Membranes

We are studying whether a short-term treatment can help pregnant individuals with PPROM before 34 weeks of gestation. The goal is to see if it reduces complications for mothers and their babies.

Complicated ChildbirthConfirmation phase (III)Standard MedicinesGynecology and Obstetrics

Shingrix Vaccine: Safety in Psoriasis and Psoriatic Arthritis

We are studying the safety and immune response of the Shingrix vaccine in patients with psoriasis or psoriatic arthritis. Our goal is to see how the vaccine affects disease activity and to monitor any side effects.

Psoriatic ArthritisPsoriasis Vulgaris>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinology

Acute Heart Failure: Intra-Abdominal Pressure and Ultrasound Study

We are exploring whether using intra-abdominal pressure and ultrasound can improve diuretic treatment for patients with acute heart failure. This study aims to see if these methods help reduce congestion and improve recovery compared to standard treatment.

Acute Heart Failure>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Recurrent Lower Respiratory Tract Infections: Buccalin Tablets

We are studying Buccalin tablets to see if they can help prevent recurrent lower respiratory tract infections. This trial aims to gather more information on their safety and effectiveness.

Recurrent Lower Respiratory Tract InfectionsMonitoring phase (IV)16-20 visitsStandard MedicinesInternal MedicinePulmonology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGynecology and ObstetricsNeurology

Sepsis Treatment: New Antibiotic Dosing Strategy

We are testing a new way to dose beta-lactam antibiotics for critically ill patients with sepsis. The goal is to see if this improves their recovery in the ICU.

Sepsis1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Allopurinol for Brain Protection in Newborns with Heart Disease

We are studying whether allopurinol can help reduce brain injury in newborns with critical congenital heart disease during and after cardiac surgery. This trial will also assess its effects on brain and heart function, as well as overall development.

Brain Injury in Neonates with Congenital Heart Disease>2 yearsConfirmation phase (III)Standard MedicinesCardiologyNeurologyPediatrics

Frozen Shoulder Treatment: Corticosteroid Injection with Nerve Block

We are studying whether a corticosteroid injection combined with a nerve block provides better pain relief and shoulder function than an injection with a placebo. This trial aims to help improve treatment strategies for patients with Frozen Shoulder.

Frozen ShoulderAdhesive Capsulitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics
1...5051525354...90